Citadel Advisors’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$234K Sell
333,088
-1,155,730
-78% -$1.08M ﹤0.01% 11068
2025
Q4
$2.31M Buy
1,488,818
+685,752
+85% +$1.1M ﹤0.01% 5643
2025
Q3
$1.27M Sell
803,066
-225,009
-22% -$391K ﹤0.01% 7028
2025
Q2
$2.24M Buy
1,028,075
+790,433
+333% +$1.91M ﹤0.01% 5492
2025
Q1
$649K Sell
237,642
-139,956
-37% -$552K ﹤0.01% 7900
2024
Q4
$1.57M Buy
377,598
+327,025
+647% +$1.24M ﹤0.01% 6126
2024
Q3
$197K Buy
50,573
+31,235
+162% +$132K ﹤0.01% 10173
2024
Q2
$75.8K Sell
19,338
-36,561
-65% -$157K ﹤0.01% 11272
2024
Q1
$234K Sell
55,899
-79,156
-59% -$372K ﹤0.01% 9991
2023
Q4
$635K Buy
135,055
+86,981
+181% +$339K ﹤0.01% 7601
2023
Q3
$150K Buy
48,074
+30,662
+176% +$123K ﹤0.01% 10352
2023
Q2
$79.9K Sell
17,412
-130,943
-88% -$602K ﹤0.01% 11256
2023
Q1
$734K Sell
148,355
-1,981,690
-93% -$9.76M ﹤0.01% 7461
2022
Q4
$11.6M Buy
2,130,045
+967,771
+83% +$5.93M ﹤0.01% 2622
2022
Q3
$7.55M Sell
1,162,274
-169,068
-13% -$943K ﹤0.01% 3182
2022
Q2
$6.3M Sell
1,331,342
-165,418
-11% -$815K ﹤0.01% 3386
2022
Q1
$10.5M Buy
1,496,760
+1,477,221
+7,560% +$10.1M ﹤0.01% 2873
2021
Q4
$199K Buy
+19,539
New +$210K ﹤0.01% 11862

Other funds holding MXCT

Citadel Advisors's MXCT Position: Q1 2026 in Review

Citadel Advisors reduced its MaxCyte (MXCT) stake by 78% in Q1 2026, selling an estimated $1.08M and leaving 333,088 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #11068.

Citadel Advisors first reported a position in MXCT in Q4 2021 and has held it in 18 quarters since. The position peaked at $11.6M in Q4 2022. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Citadel Advisors held 333,088 shares of MaxCyte worth $234K as of Q1 2026.
  • Citadel Advisors sold 1,155,730 MaxCyte shares in Q1 2026, an estimated $1.08M.
  • MaxCyte made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11068 holding.
  • Citadel Advisors first reported a position in MaxCyte in Q4 2021 and has held it in 18 quarters since.
  • Citadel Advisors's MaxCyte position peaked at $11.6M in Q4 2022.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.